Union Bancaire Privee UBP SA Has $1.62 Million Stock Holdings in Stryker Corporation $SYK

Union Bancaire Privee UBP SA reduced its stake in Stryker Corporation (NYSE:SYK) by 31.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 4,592 shares of the medical technology company’s stock after selling 2,144 shares during the quarter. Union Bancaire Privee UBP SA’s holdings in Stryker were worth $1,619,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the company. Clayton Financial Group LLC bought a new position in Stryker during the 3rd quarter worth approximately $26,000. Elevation Point Wealth Partners LLC bought a new position in Stryker during the second quarter worth $28,000. Kilter Group LLC acquired a new position in Stryker in the second quarter valued at $29,000. Howard Hughes Medical Institute acquired a new stake in Stryker during the 2nd quarter worth about $29,000. Finally, United Financial Planning Group LLC bought a new position in shares of Stryker in the 3rd quarter worth about $27,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently commented on SYK. The Goldman Sachs Group set a $399.00 target price on Stryker in a research report on Friday, January 9th. Citizens Jmp raised Stryker from a “market perform” rating to an “outperform” rating and set a $440.00 price target on the stock in a research note on Friday, December 19th. BTIG Research raised their price objective on shares of Stryker from $410.00 to $412.00 and gave the stock a “buy” rating in a research report on Friday, January 30th. Jefferies Financial Group reiterated a “buy” rating and set a $465.00 target price on shares of Stryker in a research report on Wednesday, March 4th. Finally, Evercore set a $390.00 target price on shares of Stryker in a research note on Monday, January 5th. Fourteen equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to MarketBeat.com, Stryker presently has an average rating of “Moderate Buy” and an average target price of $427.50.

Stryker Trading Down 1.1%

Shares of Stryker stock opened at $335.96 on Friday. The company has a market capitalization of $128.57 billion, a P/E ratio of 39.99, a price-to-earnings-growth ratio of 1.99 and a beta of 0.85. The stock has a fifty day simple moving average of $363.25 and a 200 day simple moving average of $366.04. Stryker Corporation has a 12-month low of $328.23 and a 12-month high of $404.87. The company has a current ratio of 1.89, a quick ratio of 1.21 and a debt-to-equity ratio of 0.66.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Thursday, January 29th. The medical technology company reported $4.47 earnings per share for the quarter, beating the consensus estimate of $4.40 by $0.07. Stryker had a return on equity of 24.41% and a net margin of 12.92%.The business had revenue of $7.17 billion for the quarter, compared to analysts’ expectations of $7.12 billion. During the same period last year, the business earned $4.01 EPS. The business’s revenue was up 11.4% on a year-over-year basis. On average, sell-side analysts anticipate that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Stryker Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, April 30th. Investors of record on Tuesday, March 31st will be given a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date of this dividend is Tuesday, March 31st. Stryker’s dividend payout ratio (DPR) is presently 41.90%.

Insiders Place Their Bets

In other Stryker news, Director Ronda E. Stryker sold 250,000 shares of the company’s stock in a transaction dated Wednesday, February 4th. The shares were sold at an average price of $362.92, for a total value of $90,730,000.00. Following the completion of the sale, the director directly owned 2,457,331 shares of the company’s stock, valued at approximately $891,814,566.52. This represents a 9.23% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 5.90% of the company’s stock.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.